web analytics
13.2 C
Munich
Monday, September 20, 2021

Rushnet Inc (OTCMKTS: RSHN) Major Runner as heliosDX Launches 6 Part Interview Series Airing on National TV

Rushnet Inc (OTCMKTS: RSHN) is racing up the charts after the Company announced it and its recently acquired subsidiary heliosDX will conduct a 6 Part interview series to be conducted by FMW Media’s New to The Street/ Newsmax that will be carried by a number of nationwide media outlets including Fox Business, Bloomberg Network, Newsmax, KRON, RNN, and potentially other outlets. The reach of these networks is in excess of over 300 million homes. RSHN is under heavy accumulation and volume has picked up substantially as the stock looks to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension; a break over $0.0249 and its blue skies ahead. 

RushNet, Inc recently acquired heliosDX, a National Diagnostics Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. heliosDX is contracted in 44 of the lower 48 states and looking to expand its reach and capabilities. hiliosDX is CLIA Certified, HIPAA compliant and was recently recognized by COLA for its laboratory excellence. heliosDX is currently doing around $1.5 million in revenues per quarter and is on track to do $5 to $6 million in revenues in 2021. heliosDX being acquired by RushNet was the first milestone for heliosDX realizing its goal to becoming a fully reporting standalone company trading under its own symbol. The company is currently preparing its applications for FINRA, SEC and disclosures. The timing of the interviews could not have come at a more perfect time for heliosDX as the Company prepares to launch a National Sales Campaign utilizing Verb Technology Company cutting edge interactive sales and marketing platform (verbTEAMS and verbLIVE).  

Rushnet Inc (OTCMKTS: RSHN) has been operating as a edible and beverage-based company which recently acquired heliosDX; a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. heliosDX is contracted in 44 of the lower 48 states and looking to expand its reach and capabilities. Always staying ahead of the curve, by continually investing in its infrastructure with the most efficient scientific proven instruments, and latest cutting-edge software for patient and physician satisfaction. This allows heliosDX to provide physicians fast and accurate reporting meeting and exceeding industry benchmarks. The Company excels in patient and client care through physician designed panels that aid in testing compliance and reporting education. heliosDX as the first step to bring value to shareholders. The has company progressed in the last few months and plans future acquisitions to bolster company and shareholder value. 

Q2 was another record quarter for heliosDX. In the 1st Quarter of 2021, heliosDX generated a record $1,252,000 in revenue. This was a new company benchmark. In April and May 2021, heliosDX has generated revenues totaling approximately $990,000 respectively. This is an average of $495,000 a month. This also includes another record of approximately $530,000 in revenue for the month of May. This growth puts heliosdDX on pace to hit their stretch projected 2nd quarter target of $1.4 to $1.5 million. This again sets another company benchmark. This would equate to just over a 20% revenue growth quarter over quarter. heliosDX enjoyed a 70%+ revenue growth from 2019 to 2020, and to see the growth continue speaks volumes to the execution of the plan, and the staff at heliosDX. 

For the Inside Scoop on Rushnet Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

RSHN

Microcapdaily has been reporting on RSHN for years starting in October 2018 stating at the time: “Rushnet Inc (OTCMKTS: RSHN) has been on the rise again in recent days; the stock is a volume leader with a long history of big moves running from triple zeros to highs of $0.008 earlier this year. Rushnet has attracted a large shareholder base who continues to bid this one higher. RSHN is at the right place at the right time; the cannabidiol (CBD) market is expected to hit $591 million this year, and it may grow 40 times this size—to $22 billion by 2022 – meaning that hemp-derived CBD could outpace all other cannabis markets, according to a new report by Brightfield Group. 

heliosDX previously announced there will be a dividend of 1 share of heliosDX for every 800 shares of RushNet owned upon close of the ex-dividend date. RushNet shareholders have access to purchase 11 additional shares of heliosDX per 1,000 shares of Rushnet, Inc at a 50% to market upon the close on the ex-dividend date. For every 10 shares purchased at the discount to market of 50% the shareholder receives one additional share of heliosDX. heliosDX will also include the ability to convert qualified shares of Rushnet into heliosDX upon the split-off. A qualified share of RushNet is a share owned on the close of the ex-dividend date. The conversion ratio is yet to be determine but is customarily done at an equal value with an incentive percentage to convert. The incentive percentage has not been determined but will not be less than 10%. 

We have a Monster Pick Coming. Subscribe Right Now!

RSHN is racing up the charts after the Company announced it and its recently acquired subsidiary heliosDX will conduct a 6 Part interview series to be conducted by FMW Media’s New to The Street/ Newsmax that will be carried by a number of nationwide media outlets including Fox Business, Bloomberg Network, Newsmax, KRON, RNN, and potentially other outlets. The reach of these networks is in excess of over 300 million homes. RushNet, Inc recently acquired heliosDX, a National Diagnostics Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. heliosDX is contracted in 44 of the lower 48 states and looking to expand its reach and capabilities. hiliosDX is CLIA Certified, HIPAA compliant and was recently recognized by COLA for its laboratory excellence. heliosDX is currently doing around $1.5 million in revenues per quarter and is on track to do $5 to $6 million in revenues in 2021. heliosDX being acquired by RushNet was the first milestone for heliosDX realizing its goal to becoming a fully reporting standalone company trading under its own symbol. The company is currently preparing its applications for FINRA, SEC and disclosures. The timing of the interviews could not have come at a more perfect time for heliosDX as the Company prepares to launch a National Sales Campaign utilizing Verb Technology Company cutting edge interactive sales and marketing platform (verbTEAMS and verbLIVE). RSHN is under heavy accumulation and volume has picked up substantially as the stock looks to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension; a break over $0.0249 and its blue skies ahead. We will be updating on RSHN when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with RSHN.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in RSHN either long or short and we have not been compensated for this article.

More articles

1 COMMENT

  1. OTCM ticker of the year! Don’t hesitate to get in on this now before it’s over a dollar. From there it’s uplisting to the NASDAQ and the sky’s the limit. Early warning system on full alert.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.